epirubicin has been researched along with Hyperthyroidism in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blohmer, JU; Burchardi, N; Denkert, C; Engels, K; Fasching, PA; Furlanetto, J; Grischke, EM; Hanusch, C; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Rautenberg, B; Rezai, M; Rhiem, K; Schmitt, WD; Schneeweiss, A; Sinn, BV; Tesch, H; Thomalla, J; Untch, M; von Minckwitz, G; Weber, K | 1 |
1 trial(s) available for epirubicin and Hyperthyroidism
| Article | Year |
|---|---|
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Breast; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Hyperthyroidism; Hypothyroidism; Lymphocytes, Tumor-Infiltrating; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Placebos; Prospective Studies; Receptor, ErbB-2; Thyroid Gland; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2019 |